Vylor Inc. (VYLR) Stock Price & How to Invest

Vylor, Inc. is the advanced seed and genetics company separated from Corteva on October 1, 2026, headquartered in Johnston, Iowa and led by CEO Chuck Magro, who previously ran Corteva. It holds what was Corteva's seed segment, the business built on Pioneer, which sells hybrid corn, soybean and other seed with patented traits to farmers across North America, Latin America and beyond, and had roughly 12,300 employees at the end of 2025, about 73% of them in the Americas. In 2025 that segment generated ~$9.9 billion of net sales (up ~4%) and ~$2.6 billion of operating EBITDA, a ~27% margin that rose ~340 basis points as Corteva shifted soybean acres onto its own Enlist E3 traits and cut royalties paid to rivals. Corteva shareholders received one Vylor share for each Corteva share, and Vylor joined the S&P 500 on its first day of trading.

The investment case management laid out at its September 15, 2026 investor day rests on growth beyond the base seed business: a ~$19 billion technology pipeline with 12 platform launches in corn, soybeans and wheat over the next decade, Xpedite hybrid wheat from late 2027, gene editing, and a licensing arm (Vylor One) targeted at more than $500 million of gross licensing income in 2027 and ~$2 billion by 2040. The 2029 targets are ~$11.2 billion to ~$11.9 billion of net sales (3% to 4% annual growth) and ~$3.3 billion to ~$3.7 billion of operating EBITDA. Against that, the stock closed at ~$73.15 on October 9 for a ~$48.8 billion market value, a rich multiple for a business that grows in low single digits, and 15 states filed suit in Indiana on October 1 alleging the spinoff was structured to leave DuPont-era PFAS liabilities behind at Corteva.

Corn carries the business. Of the ~$9.9 billion of 2025 seed sales, corn was ~$7.0 billion (about 71%), soybeans ~$1.9 billion (19%), other oilseeds such as sunflower ~$644 million, and everything else ~$374 million. By region, the U.S. and Canada took ~$6.3 billion (63%), Latin America ~$1.6 billion (Brazil alone ~$1.16 billion), Europe, the Middle East and Africa ~$1.56 billion and Asia Pacific ~$453 million. Sales are heavily seasonal: about 73% of 2025 revenue landed in the first half, when Northern Hemisphere farmers take delivery for spring planting, and first-half 2026 sales rose 4% to ~$7.56 billion. The Form 10's pro forma figures put 2025 research and development spending at ~$979 million, about a tenth of sales, which is the budget behind the trait and gene-editing pipeline.

The most immediate risk is legal: 15 states and Guam filed suit on October 1, 2026 alleging the spinoff was a fraudulent transfer meant to shield Corteva's best assets from PFAS claims, and the coalition has asked the Marion County court for a temporary restraining order to preserve assets, and Tennessee filed its own suit against EIDP, Corteva and Vylor on October 5. California had separately asked the federal PFAS court in South Carolina on September 14 to freeze Corteva assets, and the spin-off still closed on schedule. Under the separation agreement, Corteva keeps historical PFAS and other legacy EIDP environmental liabilities except those primarily related to the seed business, and certain shared corporate liabilities are split 62% to Vylor and 38% to Corteva. The state suits ask courts to look past that allocation, and an adverse outcome could pull Vylor into liabilities it was not meant to carry. Seed demand is tied to farm income, so low corn and soybean prices, high input costs or a shift in acres between corn and soybeans can pressure volumes and pricing. About 63% of 2025 sales came from the U.S. and Canada, so a weak U.S. corn year hits hard, and Latin American results bring currency and credit exposure. The pipeline targets run to 2035 and 2040, so a large part of the valuation rests on launches that have not happened yet, while Bayer, Syngenta and BASF compete for the same acres.

8 analysts publish price targets on VYLR, averaging $83.71 against a $73.15 price as of October 2026, or +14.4%. The published targets run from $78.00 to $87.00, a narrow spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VYLR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Vylor Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Proprietary traits replacing licensed ones. Most of the recent margin gain came from moving soybean acres onto Enlist E3 and other in-house traits, which reduces royalties paid to Bayer. The most optimistic published target, $87.00, assumes this works close to its best case.

The case against. The most immediate risk is legal: 15 states and Guam filed suit on October 1, 2026 alleging the spinoff was a fraudulent transfer meant to shield Corteva's best assets from PFAS claims, and the coalition has asked the Marion County court for a temporary restraining order to preserve assets, and Tennessee filed its own suit against EIDP, Corteva and Vylor on October 5. The most pessimistic target, $78.00, is roughly what VYLR is worth if this bites instead.

Read the full bull and bear case on VYLR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Vylor Inc.'s investor relations page or your broker.

• Net sales (2025, seed segment): ~$9.9 billion
• Operating EBITDA (2025): ~$2.6 billion (~27% margin)
• Share price: ~$73 (Oct 9, 2026 close)
• Market cap: ~$48.8 billion
• EV / 2025 operating EBITDA: ~18-19x
• 2029 target operating EBITDA: ~$3.3-3.7 billion

Vylor has only traded since October 1, 2026 and has not yet reported a quarter as a standalone company; its first results are scheduled for November 11, 2026. Data providers that show ~$17.8 billion of trailing revenue are carrying over Corteva's combined history, so the seed segment figures are the cleaner base. Debt at launch includes ~$1.1 billion of investment-grade senior notes due 2031 and 2036. Vylor distributed 667,302,930 shares, and the Form 10's pro forma 2025 income statement shows ~$10.1 billion of net sales after separation adjustments and ~$175 million of interest expense, equal to about 7% of 2025 operating EBITDA.

Other names that sit close to VYLR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VYLR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VYLR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VYLR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Vylor is a high-margin, slow-growing seed franchise priced at a premium for its trait and licensing pipeline, with the states' PFAS spinoff lawsuit as the main open question in its first year of trading.

Whether VYLR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VYLR a buy or a sell?, and where the stock could go from here in the VYLR stock forecast.

For income investors, whether VYLR pays a dividend and how the payout looks is covered in does VYLR pay a dividend? And to weigh VYLR against a peer, read the full side-by-side comparisons: VYLR vs GLW and VYLR vs LIN.